XBIT: XBiotech Inc. Stock

by  •  • Comments Off on XBIT: XBiotech Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 90.24
Enterprise Value ($M) -72.18
Book Value ($M) 182.27
Book Value / Share 5.98
Price / Book 0.50
NCAV ($M) 157.74
NCAV / Share 5.17
Price / NCAV 0.57

Profitability (mra)
Return on Invested Capital (ROIC) -0.20
Return on Assets (ROA) -0.17
Return on Equity (ROE) -0.18

Liquidity (mrq)
Quick Ratio 11.56
Current Ratio 11.56

Balance Sheet (mrq) ($M)
Current Assets 174.57
Assets 199.09
Liabilities 16.82
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -42.47
Net Income -38.53
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -30.96
Cash from Investing -1.30
Cash from Financing 10.45

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
01-27 13G/A Mckenzie W Thorpe 9.71 0.55
01-27 13G/A Simard John 19.90 0.19

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-03-18 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ Transaction Report pursuant to Sect
2024-11-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-08-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-05-10 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-05-01 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 2) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION R
2024-04-24 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION R

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-04-17 4,415 39,385 11.21
2025-04-16 18,469 53,476 34.54
2025-04-15 3,218 27,262 11.80
2025-04-14 6,907 28,043 24.63

(click for more detail)

Similar Companies
VTRS – Viatris Inc. VTYX – Ventyx Biosciences, Inc.
VYGR – Voyager Therapeutics, Inc. XERS – Xeris Biopharma Holdings, Inc.
XLO – Xilio Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io